2-苄基-3-氧代丁酸 | 2382-58-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 2-苄基-3-氧代丁酸
• 英文名称: 2-benzyl-3-oxobutanoic acid
• CAS: 2382-58-3
• 化学式: C₁₁H₁₂O₃
• 分子量: 192.214
• InChiKey: WXRKHHZAGZHEHZ-UHFFFAOYSA-N

物化性质

• 沸点：
  327.0±30.0 °C(Predicted)
• 密度：
  1.172±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-苄基-3-氧代丁酸 在 三氟甲磺酸 作用下， 以 二氯甲烷 为溶剂， 反应 7.0h， 以70%的产率得到3-甲基茚-2-羧酸
  参考文献：
  名称：

  Cyclization of Arylacetoacetates to Indene and Dihydronaphthalene Derivatives in Strong Acids. Evidence for Involvement of Further Protonation of O,O-Diprotonated β-Ketoester, Leading to Enhancement of Cyclization

  摘要：

  The chemical features, such as substrate stability, product distribution, and substrate generality, and the reaction mechanism of Bronsted superacid-catalyzed cyclization reactions of aromatic ring-containing acetoacetates (beta-ketoesters) were examined in detail. While two types of carbonyl cyclization are possible, i.e., keto cyclization and ester cyclization, the former was found to take place exclusively. The reaction constitutes an efficient method to synthesize indene and 3,4-dihydronapthalene derivatives. Acid-base titration monitored with C-13 NMR spectroscopy showed that the acetoacetates are fully O-1,O-3-diprotonated at H-0 = -11. While the five-membered ring cyclization of the arylacetoacetates proceeded slowly at H-0 = -11, a linear increase in the rate of the cyclization was found with increasing acidity in the high acidity region of H-0 = -11.8 to -13.3. Therefore, the O-1,O-3-diprotonated acetoacetates exhibited some cyclizing reactivity, but they are not the reactive intermediates responsible for the acceleration of the cyclization in the high acidity region. The reactive cationic species might be formed by further protonation (or protosolvation) of the O-1,O-3-diprotonated acetoacetates; i.e., they may be tricationic species. Thermochemical data on the acid-catalyzed cyclization of the arylacetoacetates showed that the activation energy is decreased significantly as compared with that of the related acid-catalyzed cyclization reaction of a compound bearing a single functional group, such as a ketone. These findings indicate that intervention of the trication contributes to the activation of the cyclization of arylacetoacetates in strong acid, and the electron-withdrawing nature of the O-protonated ester functionality significantly increases the electrophilicity of the ketone moiety.

  DOI：

  10.1021/ja908749u
• 作为产物：
  描述：

  2-苄基乙酰乙酸乙酯 在 水 、 sodium hydroxide 作用下， 生成 2-苄基-3-氧代丁酸
  参考文献：
  名称：

  铱催化的Z-保留不对称烯丙基取代反应对映选择性合成中环内酯

  摘要：

  中等大小的环是重要的结构单元，但它们的合成，特别是以高度对映选择性的方式，一直是一个巨大的挑战。在这里，我们报告了通过铱催化的Z保持不对称烯丙基取代反应对中型环内酯的对映选择性合成。该反应条件温和，底物范围广。各种 8 至 11 元环内酯可以中等至优异的产率（高达 88%）和优异的对映选择性（高达 99% ee）提供。Z-烯丙基前体和 Ir 催化剂的利用对于中等环的形成至关重要。

  DOI：

  10.1021/jacs.2c01103

文献信息

• Double decarboxylative route to 3-substituted pyrrolidines: Reaction of monoalkyl malonates and related carboxylic acids with sarcosine and formaldehyde
  作者：Evgeny M. Buev、Anastasia A. Smorodina、Vladimir S. Moshkin、Vyacheslav Y. Sosnovskikh

  DOI：10.1016/j.tetlet.2020.151727

  日期：2020.4

  Three-component reactions of monoalkyl malonates, cyanoacetic acids or 2-ketocarboxylic acids, N-methylglycine, and formaldehyde were developed to rapidly access 3-substituted pyrrolidines in 17–97% yield. These reactions represent a double decarboxylative domino-sequence promoted by pyrrolidine and involve N-methylazomethine ylide as the reactive intermediate. 2020 Elsevier Ltd. All rights reserved

  开发了丙二酸单烷基酯，氰基乙酸或2-酮羧酸，N-甲基甘氨酸和甲醛的三组分反应，以17-97％的产率快速获得3-取代的吡咯烷。这些反应代表由吡咯烷促进的双脱羧多米诺序列，并且涉及N-甲基偶氮甲亚胺叶立德作为反应性中间体。2020 Elsevier Ltd.保留所有权利。
• [EN] BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME<br/>[FR] COMPOSÉS ÉMISSIFS CYCLIQUES CONTENANT DU BORE ET FILM DE COLORISATION CONTENANT CEUX-CI
  申请人：NITTO DENKO CORP

  公开号：WO2020210761A1

  公开（公告）日：2020-10-15

  The present disclosure relates to novel photoluminescent complexes comprising a BODIPY moiety covalently bonded to a blue light absorbing moiety, a color conversion film comprising the photoluminescent complex, and a back-light unit using the same.

  本公开涉及新型的光致发光配合物，该配合物包括与蓝色光吸收基团共价键结合的BODIPY部分，包含该光致发光配合物的色转换膜，以及使用该配合物的背光单元。
• Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20030064991A1

  公开（公告）日：2003-04-03

  Disclosed are novel compounds having the formula 1 or a physiologically acceptable salt, amide, ester or prodrug thereof. The compounds can be used to modulate (antagonize, agonize) chemokine receptor function. Also disclosed is a method for treating a patient having an inflammatory disease and/or viral infection comprising administering an effective amount of a compound of Formula I. In particular embodiments, the invention is a method for treating a patient infected with HIV.

  揭示了具有以下结构式的新化合物 1 或其生理上可接受的盐、酰胺、酯或前药。这些化合物可用于调节（拮抗、激动）趋化因子受体功能。还揭示了一种治疗患有炎症性疾病和/或病毒感染的患者的方法，包括给予结构式I的化合物的有效量。在特定实施例中，本发明是一种治疗感染HIV的患者的方法。
• SUBSTITUTED HETEROCYCLIC COMPOUNDS
  申请人：Abelman Matthew

  公开号：US20090012103A1

  公开（公告）日：2009-01-08

  The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.

  本发明涉及新颖的杂环化合物及其在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，化合物的结构由公式（I）给出：其中Q1、Q2、R2、R3、R4、R5和R6如本文所述。该发明还涉及制备这些化合物的方法，以及含有这些化合物的药物组合物。
• [EN] 6 - METHYL - 4 - PHENYL - 5 - ( PHENYL OR CYCLOALKYL) CARBAMOYL - 1,2,3, 4 - TETRAHYDROPYRIMIDIN- 2 - ONE DERIVATIVES AS ANTITUBERCULAR AGENTS<br/>[FR] DÉRIVÉS DE 6 - MÉTHYL - 4 - PHÉNYL - 5 - (PHÉNYL OU CYCLOALKYL) CARBAMOYL - 1,2,3, 4 - TÉTRAHYDROPYRIMIDIN- 2 - ONE UTILISÉS EN TANT QU'AGENTS ANTITUBERCULEUX
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2011151701A1

  公开（公告）日：2011-12-08

  The present invention discloses antitubercular compounds selected from tetrahydropyrimidones/ tetrahydrothiopyrimidone derivatives of Formula (1) and its pharmaceutically acceptable salts for the treatment of Mycobacterium in the dormant phase. Formula (1) wherein, R is H, halogen, dihalogen, O-alkyl, di- O-alkyl, R1 is phenyl, chlorophenyl, nitrophenyl, diclorophenyl, cycloalkyl, preferably cyclohexyl, X is O or S.

  本发明公开了选择自公式（1）的四氢嘧啶酮/四氢硫嘧啶酮衍生物以及其药学上可接受的盐的抗结核化合物，用于治疗休眠期结核分枝杆菌。其中，公式（1）中，R为H、卤素、二卤素、O-烷基、二O-烷基，R1为苯基、氯苯基、硝基苯基、二氯苯基、环烷基，优选环己基，X为O或S。